AA
REGN icon

Armis Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Armis Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-294
Closed -$215K – 474
2025
Q4 		$215K Sell
294
-18
-6% -$12.2K 0.02% 403
2025
Q3 		$200K Buy
+312
New +$176K 0.02% 314

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Armis Advisers's REGN Position: Q1 2026 in Review

Armis Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 294 shares — an estimated $215K sold.

Armis Advisers first reported a position in REGN in Q3 2025 and held it in 2 quarters. The position peaked at $215K in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Armis Advisers reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Armis Advisers sold 294 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $215K.
  • Armis Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Armis Advisers's Regeneron Pharmaceuticals position peaked at $215K in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Armis Advisers's 13F filing for Q1 2026, filed 15 May 2026.